Unknown

Dataset Information

0

Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial.


ABSTRACT: BACKGROUND:First-line rituximab therapy together with chemotherapy is the standard care for patients with advanced follicular B-cell lymphoma, as rituximab together with chemotherapy prolongs progression-free and overall survival (Herold et al. 2007; Marcus et al. 2005). However, as not all patient subgroups benefit from combined immuno-chemotherapy, we asked whether the microenvironment may predict benefit from rituximab-based therapy. DESIGN:To address this question, we performed a retrospective immunohistochemical analysis on pathological specimens of 18 patients recruited into a randomized clinical trial, where patients with advanced follicular lymphoma were randomized into either chemotherapy or immuno-chemotherapy with rituximab (Herold et al. 2007). RESULTS:We show here that rituximab exerts beneficial effects, especially in the subgroup of follicular lymphoma patients with low intrafollicular CD3, CD5, CD8, and ZAP70 and high CD56 and CD68 expression. CONCLUSION:Rituximab may overcome immune-dormancy in follicular lymphoma in cases with lower intrafollicular T-cell numbers and higher CD56 and CD68 cell counts. As this was a retrospective analysis on a small subgroup of patients, these data need to be corroborated in larger clinical trials.

SUBMITTER: Budau L 

PROVIDER: S-EPMC6658576 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial.

Budau Laura L   Wilhelm Christian C   Moll Roland R   Jäkel Jörg J   Hirt Carsten C   Dölken Gottfried G   Maschmeyer Georg G   Neubauer Ellen E   Strauch Konstantin K   Burchert Andreas A   Herold Michael M   Neubauer Andreas A  

Journal of cancer research and clinical oncology 20190704 8


<h4>Background</h4>First-line rituximab therapy together with chemotherapy is the standard care for patients with advanced follicular B-cell lymphoma, as rituximab together with chemotherapy prolongs progression-free and overall survival (Herold et al. 2007; Marcus et al. 2005). However, as not all patient subgroups benefit from combined immuno-chemotherapy, we asked whether the microenvironment may predict benefit from rituximab-based therapy.<h4>Design</h4>To address this question, we performe  ...[more]

Similar Datasets

| S-EPMC3436246 | biostudies-literature
| S-EPMC5757687 | biostudies-literature
| S-EPMC7571803 | biostudies-literature
| S-EPMC3837631 | biostudies-literature
| S-EPMC4755793 | biostudies-literature
| S-EPMC6486816 | biostudies-literature
| S-EPMC6051161 | biostudies-literature
| S-EPMC6748924 | biostudies-literature
| S-EPMC7735159 | biostudies-literature
2008-12-05 | E-GEOD-10846 | biostudies-arrayexpress